演讲嘉宾

JP; MBBS(HK); ChM(Liv); FRCS(Eng, Edin, Glas, and Ire); FRCPCH; FHKAM (Surgery);HKAS member Prof. Paul K.H. Tam is a renowned surgeon, scientist, educator and university leader. He is Chair Professor and Vice-President of the Macau University of Science and Technology, and Emeritus Professor and Honorary Clinical Professor of the University of Hong Kong Professor Tam has special interests in minimal invasive surgery, genetics and regenerative medicine of birth defects especially Hirschsprung’s disease and biliary atresia. He has published 505 articles in internationally refereed journals with 35,314 citations and h-index = 66. He has received numerous awards including the 2017 Denis Browne Gold Medal- the highest award of the BAPS, the 2020 Rehbein Medal by the European Paediatric Surgeons’ Association.

上海市瑞⾦医院南翔分院中⼼实验室主任，博⼠，副研究员，硕⼠研究⽣导师，上海市中医药重点学科后备学科带头⼈，兼中国神经科学学会感觉与运动专业委员会委员、中华中医药学会脑病分会⻘年委员。主要从事难治性癫痫发⽣机制及个体化治疗的研究。⼊选中华中医药⻘年⼈才托举⼯程、上海市东⽅英才⻘年计划、“医苑新星”杰出⻘年医学⼈才、卫⽣系统“银蛇奖”提名奖及银蛇奖-恒杰专项扶植计划。以第⼀、共⼀或通讯作者在 J Hepatol、BJP、JMC 及 Acta Pharmacol Sin 等学术期刊上发表 SCI 论⽂ 37篇。以第⼀完成⼈获得上海中医药科技⼆等奖，主参编国内外书籍 7 本，申报国家发明专利 12 项，已授权 2 项。先后承担 4 项国家⾃然科学基⾦项⽬，参与 2 项国家科技部“973”项⽬⼦课题和 1 项国家重点研发计划重点专项。
.
.
.
.
.
.
.

Prof. Tse Hung-Fat, MBBS, MD, PhD, FACC, FRCP, FESC Prof. Hung-Fat Tse is Chair Professor of Cardiovascular Medicine, and William MW Mong Professor in Cardiology; Chairpersons and Chief of Service of the Department of Medicine; Chief in the Cardiology Division, Department of Medicine, Queen Mary Hospital; Co director, Cardiac & Vascular Center, The University of Hong Kong – Shenzhen Hospital. He is also the academic lead, HKUMed Laboratory of Cellular Therapeutics, The University of Hong Kong. He is a clinician scientist and an international expert in cardiovascular medicine, including cardiac pacing, clinical electrophysiology, and cardiovascular regeneration. Prof. Tse is one of the pioneers for novel therapies, including stem cell and devices for treatment of cardiovascular diseases. He has established the large animal laboratory for cardiovascular research as well the “Good Manufacturing Practice” laboratory for human stem cells and biological therapies in the University of Hong Kong. He has been awarded multiple major local grants (including the Theme Based Research Grant, Research Impact Fund and Innohealth) as well as national research grants (National Natural Science Foundation of China and 973 grants) for his researches. He has been participated into many international and regional clinical trials and studies, and is currently the Associate Editors for several international journals, including Cardiovascular Diabetology, Frontier in Cardiovascular Medicine, Journal of Cardiovascular Electrophysiology, Pacing and Clinical Electrophysiology and Journal of Arrhythmia. He has published over 730 scientific publications in international top-ranking scientific journals, including New England Journal of Medicine, Lancet, Nature Medicine, Nature Cell Biology, Nature Genetic, Nature Protocol, Nature Communication, Nature Biomedical Engineering, Nature Disease Primer, Cell Stem Cell, Circulation, Journal of American College of Cardiology, and European Heart Journal.

王红杰 博⼠，教授，主任医师，博⼠研究⽣导师，河北⼤学基础医学院院长。毕业于河北医科⼤学，获麻醉学硕⼠学位和药理学博⼠学位，历任河北⼤学附属医院麻醉科副主任、科研处处长和河北⼤学医学院副院长。现兼任教育部⾼等学校教学指导委员会麻醉学专业教学指导分委员会委员，河北省医学会麻醉学分会委员，《中华麻醉学杂志》通讯编委。

王宇，中国肝炎防治基⾦会理事⻓。获得北京医科⼤学医学博⼠、⽇本⾃治医科⼤学理学博⼠学位。专业背景是病毒分⼦⽣物学和免疫学，曾从事肝炎病毒及所致疾病的研究。先后担任北京医科⼤学肝病研究所所⻓、北京医科⼤学副校⻓、中国⽣物技术发展中⼼副主任、科技部农村与社会发展司副司⻓。2004 年-2017 年任中国疾病预防控制中⼼主任。现担任中华医学会常务理事、国家免疫规划专家咨询委员会委员和世界卫⽣组织⻄太区消灭脊髓灰质炎证实委员会委员。

张海⽣博⼠，希格⽣科创始⼈兼 CEO，现任深圳清华⼤学研究院癌症靶向治疗研 发中⼼主任，南⽅医科⼤学南⽅医院双聘教授。
曾于哈佛⼤学 Dana-Farber 癌症 研究所和 MIT 博德研究所从事博⼠后研究，长期致⼒于胃癌靶向治疗与伴随诊断 研究。
以第⼀或通讯作者身份在 Cancer Discovery、Gut 等国际权威期刊发表论⽂ ⼗余篇，
首次发现弥漫性胃癌关键靶点。
2020 年创办希格⽣科，聚焦“类器官+AI” 平台驱动的新药研发，已建立三条创新管线，包括全球首款针对弥漫性胃癌的靶 向药 SIGX1094，现正在北京⼤学肿瘤医院开展⼀期临床试验并获 FDA 孤⼉药资格 认定与快速通道认定。
张博⼠曾获“深圳⼗⼤杰出青年企业家”新锐青年、 36 氪“36 位 36 岁以下创业者”等荣誉。

Dr. Jiayi Zhang received her B. Sc. Degree from Hong Kong Baptist University and Ph.D. degree from Brown University. She was a Brown-Coxe postdoctoral fellow in Yale University and joined Institutes of Brain Science at Fudan University in 2012. Her recent work focused on the decoding and restoration of vision. Her work was published in journals including Science, Nature Biomedical Engineering, Neuron and Nature Communications （ 3 ） . She received the State Science and Technology Advancement Award in 2023 and the Young Innovative Woman Award in Shanghai in 2020. She serves as the Vice chairman of the Neurotechnology Panel, Chinese Neuroscience Society (CNS). She is on the editorial board of Progress in Retina and Eye Research. She is currently the vice director of State Key Laboratory for Medical Neurobiology and the vice dean of Institute for Medical and Engineering Innovation at Fudan Affiliated Eye & ENT Hospital.

张宁，男，北京⼤学教授，国家“万⼈计划”⼊选者、国家杰出⻘年科学基⾦获得者、科技部中⻘年科技创新领军⼈才、⼈事部百千万⼈才、突出贡献专家美国。李⽒基⾦会杰出成就奖获得者。现担任北京⼤学第⼀医院肿瘤转化研究中⼼主任，北⼤-⽩药国际医学中⼼副主任，北京⼤学国际癌症研究院副院⻓， 北京⼤学健康⼤数据国家研究院副院⻓，中国抗癌协会常务理事、副秘书⻓，中国⽼年学和⽼年医学学会转化医学分会主任委员，《Cancer Biology & Medicine》常务副主编，《Medical Review》常务副主编， ⽩药集团⾸席科学家。张宁教授⻓期从事⽣物医学研究，⽂章发表在 Nature、Cancer Cell、Nature Biotechnology、GastroenterologyNature Communications 等国际期刊。

• .
• .
• .
• .
• .
  .
• .
  .
• .
• .
• .
  .

周国瑛，中科院上海生化所博士，国家千人，2024 年中国十大杰出创新女性, 2019 年国际“抗病毒女科学家奖”唯一获得者，2021 年中国十大杰出女企业家，2017 年“科学中国人”、1998 年“国务院特殊津贴”获得者。前芝加哥大学微生物系副教授，1999-2014 年芝加哥大学从事疱疹病毒研究，在抗病毒感染与疱疹溶瘤病毒肿瘤免疫治疗研究领域深耕近 30 年。周博士 2015 年创办亦诺微医药，迄今为止，公司建设了集完整的科学逻辑、研发技术及生产工艺为一体的 OVPENS®平台，并在此基础上发展出溶瘤病毒免疫治疗和工程化外泌体递送两大平台，用于支持 Best in Class 的单药管线与联合用药的早期研发，临床研究及商业化合作进程，满足肿瘤与非肿瘤领域的临床需求。溶瘤病毒新药产品覆盖各种实体瘤，给药途径涵盖瘤内、静脉和腔内；外泌体药物递送管线分为腔内核酸药物递送和外膜多功能多数量蛋白装载，产品覆盖大健康领域和复杂难治的代谢、免疫、呼吸、眼疾、肌肤等应用场景。

周华，中国健康管理协会副会长兼秘书长、《中国⾼新科技杂志》副理事长、诺贝尔奖获得者 之家副主席、全国科学技术名词审定委员会委员、全国中老年⽹特聘专家、新世纪管理科学与 ⼯程研究院副院长兼专家委副主任、中华慈善总会⼤健康⼯作委员会专家委副主任。具有多年 政府部门、北京三级甲等医院领导岗位⼯作经历。担任《数字健康管理理论与实践》副主编， 《食学》中小学⽣教材副主编，对全⽣命周期的健康管理及⼤健康产业有较深的研究，撰写的 多篇⽂章在新华⽹、⼈民⽹、中国⽹、今日头条、凤凰新闻等媒体刊登。